Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Becton Dickinson (BDX – Research Report), with a price ...

Piper Sandler raised the firm’s price target on Becton Dickinson (BDX) to $280 from $275 and keeps an Overweight rating on the shares. The firm ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $243.45 which represents a slight increase of $2.98 or 1.24% from the prior close of $240.47. The stock opened at $239 and ...

Atomi Financial Group Inc. lifted its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 25.3% in the ...

Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 98.2% in the ...

Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, ...

Piper Sandler's analysts increased the price target for Becton Dickinson (NYSE:BDX) shares to $280 from $275, while ...

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science ...

Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...